{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:16:43Z","timestamp":1773271003073,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006221","name":"Cordis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jcin.2012.12.125","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T05:24:12Z","timestamp":1366262652000},"page":"504-512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program"],"prefix":"10.1016","volume":"6","author":[{"given":"David E.","family":"Kandzari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin B.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Fajadet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2012.12.125_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcin.2012.12.125_bib2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jama.295.8.895","article-title":"Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial","volume":"295","author":"Morice","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2012.12.125_bib3","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2006.08.035","article-title":"Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial","volume":"48","author":"Kandzari","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib4","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1161\/CIRCULATIONAHA105.570093","article-title":"Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials","volume":"112","author":"Mauri","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jacc.2004.11.063","article-title":"Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial","volume":"45","author":"Ellis","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jacc.2007.07.084","article-title":"Angiographic surrogate endpoints in drug-eluting stent trials: a systematic evaluation based on individual patient data from eleven randomized controlled trials","volume":"51","author":"Pocock","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jcin.2010.07.008","volume":"3","author":"Leon","year":"2010","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","article-title":"2-Year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice","volume":"58","author":"Smits","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib10","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(11)61672-3","article-title":"Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomized non-inferiority trial","volume":"378","author":"Stefanini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2012.12.125_bib11","first-page":"157","article-title":"First-in-human study of Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial","volume":"1","author":"Meredith","year":"2005","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2012.12.125_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/CIRCULATIONAHA.105.591206","article-title":"Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial","volume":"114","author":"Fajadet","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib14","first-page":"76","article-title":"Safety of direct stenting with the Endeavor stent: results of the Endeavor II continued access registry","volume":"3","author":"Schultheiss","year":"2007","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2012.12.125_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jacc.2009.08.067","article-title":"A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial","volume":"55","author":"Leon","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib16","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/CIRCULATIONAHA.109.854398","article-title":"Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis","volume":"120","author":"Cook","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2011.09.018","article-title":"Examination of the in vivo mechanisms of late drug-eluting stent thrombosis","volume":"5","author":"Guagliumi","year":"2012","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib19","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jacc.2011.01.011","article-title":"The pathology of neoatherosclerosis in human coronary implants: bare-metal and drug-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","article-title":"Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?","volume":"109","author":"Virmani","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2010.05.066","article-title":"Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents","volume":"57","author":"Nakazawa","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/CIRCULATIONAHA.106.675934","article-title":"Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications","volume":"115","author":"L\u00fcscher","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib23","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","article-title":"Vascular responses to drug eluting stents: importance of delayed healing","volume":"27","author":"Finn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jcin.2012.12.125_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcin.2010.02.008","article-title":"Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents","volume":"3","author":"Guagliumi","year":"2010","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib26","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jcin.2009.10.006","article-title":"Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial","volume":"2","author":"Kim","year":"2009","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCINTERVENTIONS.108.797928","article-title":"Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses","volume":"1","author":"Hamilos","year":"2008","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2012.12.125_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1536\/ihj.49.639","article-title":"Long-term coronary endothelial function after zotarolimus-eluting stent implantation","volume":"49","author":"Shin","year":"2008","journal-title":"Int Heart J"},{"key":"10.1016\/j.jcin.2012.12.125_bib29","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jacc.2009.01.051","article-title":"A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial function","volume":"53","author":"Kim","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib30","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1161\/CIRCULATIONAHA.110.004762","article-title":"Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial","volume":"123","author":"R\u00e4ber","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2012.12.125_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jcin.2011.07.010","article-title":"Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents","volume":"4","author":"Collet","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib32","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2010.03.020","article-title":"Two-year clinical and angiographic outcomes from a randomized of polymer-free dual drug-eluting stents versus polymer-based cypher and Endeavor drug-eluting stents","volume":"55","author":"Byrne","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jcin.2010.12.014","volume":"4","author":"Kandzari","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/CIRCINTERVENTIONS.108.831800.108.831800","article-title":"Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial","volume":"2","author":"Claessen","year":"2009","journal-title":"Circ Cardiovasc Interv"},{"issue":"Suppl","key":"10.1016\/j.jcin.2012.12.125_bib35","first-page":"B8","article-title":"TCT-24 the \u201cfinal\u201d five-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent","volume":"58","author":"Leon","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2006.02.060","article-title":"Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial","volume":"48","author":"Pinto","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcin.2010.01.010","article-title":"Clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of \u201cocclustenotic\u201d reintervention in patients with intermediate lesions","volume":"3","author":"Uchida","year":"2010","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jcin.2011.06.017","article-title":"Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents","volume":"4","author":"Kandzari","year":"2011","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(10)60208-5","article-title":"Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (sort OUT III): a randomized controlled superiority trial","volume":"375","author":"Rasmussen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2012.12.125_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jcin.2012.04.008","article-title":"Three-year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents","volume":"5","author":"Maeng","year":"2012","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.jcin.2012.12.125_bib41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2010.03.086","volume":"56","author":"Park","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2012.12.125_bib42","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","article-title":"Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomized multicentre open-label controlled trial","volume":"380","author":"Camenzind","year":"2012","journal-title":"Lancet"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813005992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879813005992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:59:05Z","timestamp":1761847145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879813005992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1936879813005992"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2012.12.125","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final 5-Year Outcomes From the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2012.12.125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}